Wyeth faces more lawsuits for promoting sales despite concerns

December 1st, 2008 by Jennifer Walker-Journey

In the 1960s, a New York gynecologist wrote a book called “Feminine Forever,” in which he recommended estrogen for menopause, stating that women on the replacement drug “will be much more pleasant to live with and will not become dull and unattractive.”

Wyeth Pharmaceuticals caught wind of the book and its author’s claims that estrogen reduced a woman’s risk for both breast and genital cancers, and began distributing the book to physicians across the country. Soon after, sales of Wyeth’s drug Premarin took off, growing to more than 30 million prescriptions each year.

But the Women’s Health Initiative of 2002 showed dramatically different results, finding the use of hormone replacement therapy linked to an increased risk of , cardiovascular disease, heart attacks and blood clots.

This is the basis of at least 22 federal lawsuits that have been filed over a period of two days against Wyeth, according to The West Virginia Record.

“The and NCI studies released in July 2002 changed the way doctors and scientists viewed estrogen – not only does estrogen therapy fail to prevent disease, it substantially increases the risk of causing disease,” the suit states.

The plaintiffs claim they suffered bodily injury, pain and suffering, disability, disfigurement, mental anguish and the loss of their capacity to enjoy life. The suit contends that Wyeth should be held liable because it did not perform adequate pre-clinical testing nor did it conduct post-marketing surveillance to determine the product’s safety. Wyeth also did not provide adequate warnings of long-term use of , instead continuing to market its medication to physicians, according to the lawsuit.

The 13-count lawsuit seeks unspecified compensatory and punitive damages.

blog comments powered by Disqus

Comments are moderated and generally will be posted if they are on-topic and not abusive.